At the beginning of May I spoke with the CFO for w
Post# of 15624
(Total Views: 760)
Posted On: 06/08/2018 8:43:16 PM
At the beginning of May I spoke with the CFO for well over an hour. The purpose of the call was to get clarification on many of the statements made in the 10-K for 2017.
My very first question was with regards to the psoriasis study at Sheba:
1. QUESTION:
IS THIS STUDY STILL ON SCHEDULE?
Here are my notes in no particular order:
>Yes still on schedule.
>Hopefully will be reporting progress within 2-3 weeks.
>Phase 1 is the most important phase.
>Speed and progress is dependent on hospital timing.
>There are Two phases
>Blood test, many failed during the screening phase.
>Phase 2 is straightforward and happens in the patient's home
>Phase 2 is quick and should be finished by Q3.
Gary, his is not my forte, and I'm sure you're able to decipher its meaning better than I can.
When prompted, Yossi did say that rather than being at the mercy of the hospitals and their timelines, in future when they negotiate their contracts with them, they will be sure to include specific terms and due dates and emphasize the importance of meeting the timelines, and the consequences if they are not met. To me this is the way the contracts should be structured.
Before we get our knickers all twisted up in a knot, let's be reminded that we are still within the second fiscal quarter!
My very first question was with regards to the psoriasis study at Sheba:
Quote:
Page 5 – 7th paragraph
On February 1, 2017, following the very encouraging results that we achieved at the mid-point of a psoriasis-related study conducted by us with an Israeli research institute, we are determined to extend the size and scope of the study for the purpose, among other parameters, of checking the biological markers that have been generated to date with respect to the treatment of psoriasis (proliferation/ inhibition and several interleukins) which was conducted by such institute. Such trial results concluded that application of our unique active cannabinoid-based topical cream formulation, indicated up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis and inhibition of proliferation.
The Study of our topical Psoriasis ointment is ongoing at the dermatologic department at Sheba’s hospital and should be completed during the second fiscal quarter of 2018.
1. QUESTION:
IS THIS STUDY STILL ON SCHEDULE?
Here are my notes in no particular order:
>Yes still on schedule.
>Hopefully will be reporting progress within 2-3 weeks.
>Phase 1 is the most important phase.
>Speed and progress is dependent on hospital timing.
>There are Two phases
>Blood test, many failed during the screening phase.
>Phase 2 is straightforward and happens in the patient's home
>Phase 2 is quick and should be finished by Q3.
Gary, his is not my forte, and I'm sure you're able to decipher its meaning better than I can.
When prompted, Yossi did say that rather than being at the mercy of the hospitals and their timelines, in future when they negotiate their contracts with them, they will be sure to include specific terms and due dates and emphasize the importance of meeting the timelines, and the consequences if they are not met. To me this is the way the contracts should be structured.
Before we get our knickers all twisted up in a knot, let's be reminded that we are still within the second fiscal quarter!
(3)
(0)OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼